You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Talimogene laherparepvec - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for talimogene laherparepvec

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Binhui Biopharmaceutical Co., Ltd.Phase 1
Varun Monga, MDPhase 1/Phase 2
University of California, DavisPhase 2

See all talimogene laherparepvec clinical trials

Recent Litigation for talimogene laherparepvec

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Replimune Limited et al.2022-11-02

See all talimogene laherparepvec litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for talimogene laherparepvec Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for talimogene laherparepvec Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for talimogene laherparepvec Derived from Patent Text Search

No patents found based on company disclosures

Talimogene Laherparepvec: Market Dynamics and Financial Trajectory

Introduction

Talimogene laherparepvec, marketed as IMLYGIC™, is a groundbreaking oncolytic virus immunotherapy developed by Amgen Inc. for the treatment of unresectable melanoma. This biologic drug has carved a niche in the oncology market, and its financial trajectory and market dynamics are worth exploring in depth.

Mechanism of Action and Clinical Use

Talimogene laherparepvec is a genetically modified herpes simplex virus type 1 designed to selectively infect and kill cancer cells while also stimulating an immune response against the tumor. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic, with no bone, brain, lung, or other visceral disease[2].

Market Approval and Regulatory Milestones

IMLYGIC™ received FDA approval in 2015, marking it as the first FDA-approved oncolytic virus immunotherapy. This approval was a significant milestone, opening up new treatment avenues for melanoma patients. The drug has also received marketing authorization in several other countries, including those in the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan[1].

Market Forecast and Sales Data

The market for talimogene laherparepvec is expected to grow significantly over the coming years. According to DelveInsight, the sales data for IMLYGIC™ from 2017 to 2030 indicates a steady increase, driven by extensive research in the treatment of melanoma and incremental healthcare spending globally. The report provides historical and forecasted sales data, which will be crucial for decision-making regarding therapeutic portfolios[1].

Cost Effectiveness and Economic Analysis

A cost-effectiveness analysis conducted by the National Institute for Health and Care Excellence (NICE) compared talimogene laherparepvec with ipilimumab for treating advanced melanoma. The analysis showed that talimogene laherparepvec was associated with additional quality-adjusted life years (QALYs) compared to ipilimumab, making it a cost-effective option in certain scenarios. The study used a de novo partitioned survival model and considered various costs, including those associated with adverse events and administration[2].

Competitive Landscape

The market for melanoma treatments is competitive, with several other therapies available, including ipilimumab and pembrolizumab. However, IMLYGIC™ holds a unique position as the only FDA-approved oncolytic virus immunotherapy. The launch of late-stage emerging therapies in the near future is expected to impact the market, but talimogene laherparepvec's novel approach and established safety and efficacy profile position it strongly[1][2].

Clinical Trials and Pipeline

Talimogene laherparepvec is being explored in various clinical trials, both as a monotherapy and in combination with other treatments such as nivolumab and trabectedin. These trials aim to expand its indications and improve treatment outcomes. For instance, Phase 2 trials combining talimogene laherparepvec with nivolumab and trabectedin have shown positive results, indicating potential future growth areas for the drug[5].

Financial Performance and Revenue

Amgen's financial reports highlight the significant contribution of IMLYGIC™ to their oncology portfolio. While specific revenue figures for IMLYGIC™ are not always separately disclosed, the overall performance of Amgen's oncology segment, which includes IMLYGIC™, has been robust. For example, Amgen's total revenues in 2023 increased by 7% from the prior year, with strong growth in their oncology pipeline[3].

Market Growth Drivers

Several factors are driving the growth of the oncolytic virus immunotherapy market, including IMLYGIC™. The increasing adoption of adjuvant therapy in developed economies and favorable reimbursement policies are key drivers. Additionally, the demand for targeted and innovative cancer treatments is on the rise, which benefits IMLYGIC™ and other oncolytic virus therapies[4].

Challenges and Opportunities

Despite its market position, talimogene laherparepvec faces challenges such as competition from other immunotherapies and the need for continuous clinical trials to expand its indications. However, the drug's unique mechanism of action and the ongoing research in combination therapies present significant opportunities for growth and market expansion[1][2].

Patent and Intellectual Property

Talimogene laherparepvec has several patents granted, which protect its intellectual property and market exclusivity. The patent landscape is crucial for maintaining its competitive edge and preventing generic competition in the near future[5].

Global Market Assessment

The global market assessment for talimogene laherparepvec includes detailed analyses in seven major markets: the United States, EU5 countries, and Japan. This assessment provides insights into historical and forecasted sales, regulatory milestones, and market competitors, which are essential for strategic planning and investment decisions[1].

SWOT Analysis

A SWOT analysis of talimogene laherparepvec highlights its strengths, such as its unique mechanism of action and FDA approval. Weaknesses include the high cost of treatment and potential side effects. Opportunities lie in expanding indications through combination therapies and growing demand for innovative cancer treatments. Threats include competition from other immunotherapies and regulatory challenges[1].

Analyst Insights and Key Findings

Analyst insights suggest that talimogene laherparepvec is poised for significant growth due to its clinical efficacy and the increasing need for targeted cancer therapies. Key findings from market assessments and clinical trials underscore its potential to dominate a segment of the melanoma treatment market[1].

Future Outlook

The future outlook for talimogene laherparepvec is promising, driven by ongoing research, favorable market conditions, and the expanding need for innovative cancer treatments. As the oncolytic virus immunotherapy market continues to grow, IMLYGIC™ is well-positioned to remain a leading treatment option for unresectable melanoma.

Key Takeaways

  • Unique Mechanism: Talimogene laherparepvec is the only FDA-approved oncolytic virus immunotherapy for melanoma.
  • Market Growth: The market is expected to grow due to increasing adoption of adjuvant therapy and favorable reimbursement policies.
  • Clinical Trials: Ongoing trials are exploring its use in combination therapies, potentially expanding its indications.
  • Cost Effectiveness: It has been shown to be cost-effective compared to other treatments like ipilimumab.
  • Competitive Landscape: It holds a strong position despite competition from other immunotherapies.
  • Global Market: Detailed market assessments in seven major markets provide insights into its sales and market dynamics.

FAQs

What is talimogene laherparepvec used for?

Talimogene laherparepvec is used for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic, with no bone, brain, lung, or other visceral disease.

Who developed talimogene laherparepvec?

Talimogene laherparepvec was developed by Amgen Inc.

What is the mechanism of action of talimogene laherparepvec?

It is a genetically modified herpes simplex virus type 1 that selectively infects and kills cancer cells while stimulating an immune response against the tumor.

How does talimogene laherparepvec compare to other melanoma treatments in terms of cost-effectiveness?

According to NICE, talimogene laherparepvec is associated with additional quality-adjusted life years (QALYs) compared to ipilimumab, making it a cost-effective option in certain scenarios.

What are the potential future growth areas for talimogene laherparepvec?

Future growth areas include its use in combination therapies, as evidenced by ongoing clinical trials combining it with nivolumab and trabectedin.

Sources

  1. DelveInsight: "Talimogene Laherparepvec - Drug Insight and Market Forecast – 2030"
  2. NICE: "Talimogene laherparepvec for treating metastatic melanoma"
  3. Amgen Investors: "SHAREHOLDERS 2023"
  4. Biospace: "Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12 Percent During 2019 to 2029"
  5. Patsnap: "Talimogene laherparepvec - Drug Targets, Indications, Patents"
Last updated: 2024-12-16

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.